nach oben

Erschienen in:

10.06.2017 | Original Article

Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer

verfasst von: Matvey M. Tsyganov, Maxim B. Freidin, Marina K. Ibragimova, Irina V. Deryusheva, Polina V. Kazantseva, Elena M. Slonimskaya, Nadezhda V. Cherdyntseva, Nikolai V. Litviakov

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to investigate the association between the polymorphism and expression patterns of multiple drug resistance genes (MDR) in breast cancer (BC).

Materials and methods

The MDR gene expression levels were measured in tumor tissues of 106 breast cancer patients using quantitative real-time PCR. Affymetrix CytoScan™ HD Array chips were used to assess genotypes. Pairwise correlation analysis for ABCB1, ABCC1, ABCC2 and ABCG2 gene expression levels was carried out to reveal co-expression clusters. Associations between SNPs of MDR genes and their preoperative expression levels were assessed using analysis of covariance adjusting for covariates.

Results

The SNPs associated with the expression of the ABCB1, ABCC1, ABCC2 and ABCG2 genes before NAC were detected. In addition, 21 SNPs associated with the expression of four ABC-transporter genes and involved in the expression regulation were identified. Validation in an independent sample confirmed the association between the MDR cluster genes and 11 SNPs.

Conclusions

Four MDR genes: ABCB1, ABCC1, ABCC2 and ABCG2 were shown to form the functional expression cluster in breast tumor. Further studies are required to discover precise mechanisms of the cluster regulation, thereby providing new approaches and targets to combat the development of the MDR phenotype during chemotherapy.

Nur mit Berechtigung zugänglich

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19(5):1508–1516CrossRefPubMed

Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10(2):147–156CrossRefPubMed

Szakacs G, Varadi A, Özvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov Today 13(9):379–393CrossRefPubMed

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234CrossRefPubMed

Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV, Vtorushin SV, Zavyalova MV, Slonimskaya EM (2013) Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer Chemother Pharmacol 71(1):153–163CrossRefPubMed

Litviakov NV (2013) Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression. Sib J Oncol 4:58

Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C (1999) 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 18(46):6262–6270CrossRefPubMed

Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E (2014) TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res 24(11):1881–1893CrossRefPubMedPubMedCentral

Okudela K, Tateishi Y, Umeda S, Mitsui H, Suzuki T, Saito Y, Woo T, Tajiri M, Masuda M, Miyagi Y (2014) Allelic imbalance in the miR-31 host gene locus in lung cancer-its potential role in carcinogenesis. PLoS One 9(6):e100581CrossRefPubMedPubMedCentral

10.

Fleming JL, Dworkin AM, Allain DC, Fernandez S, Wei L, Peters SB, Iwenofu OH, Ridd K, Bastian BC, Toland AE (2014) Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. Int J Cancer 134(1):244–248CrossRefPubMed

11.

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J (2014) Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16(6):475CrossRefPubMedPubMedCentral

12.

Shen J, Medico L, Zhao H (2011) Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer. Cancer Epidemiol Biomark Prev 20(1):50–56CrossRef

13.

Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updates 15(1):50–61CrossRef

14.

Nakanishi T, Ross DD (2012) Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 31(2):73CrossRefPubMedPubMedCentral

15.

Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K (2000) Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85(2):160–165CrossRefPubMed

16.

Natarajan K, Xie Y, Baer MR, Ross DD (2012) Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83(8):1084–1103CrossRefPubMedPubMedCentral

17.

Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH (2012) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther 341(1):164–173CrossRefPubMed

18.

Vattathil S, Scheet P (2013) Haplotype-based profiling of subtle allelic imbalance with SNP arrays. Genome Res 23(1):152–158CrossRefPubMedPubMedCentral

19.

Schwartz GF, Hortobagyi GN (2004) Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Breast J 10(4):273–294CrossRef

20.

Hayward J, Carbone P, Heuson J-C, Kumaoka S, Segaloff A (1965) Rubens R (1977) Assessment of response to therapy in advanced breast cancer: a project of the programme on clinical oncology of the international union against cancer, Geneva, Switzerland. Eur J Cancer 13(1):89–94CrossRef

21.

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res 29(9):e45CrossRefPubMedPubMedCentral

22.

Litviakov NV, Cherdyntseva NV, Tsyganov MM, Slonimskaya EM, Ibragimova MK, Kazantseva PV, Kzhyshkowska J, Choinzonov EL (2016) Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy. Oncotarget 7(7):7829CrossRefPubMedPubMedCentral

23.

Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92(4):452–458CrossRefPubMed

24.

Lacave R, Coulet F, Ricci S, Touboul E, Flahault A, Rateau JG, Cesari D, Lefranc JP, Bernaudin JF (1998) Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br J Cancer 77(5):694–702CrossRefPubMedPubMedCentral

25.

Larkin A, O’Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M (2004) Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 112(2):286–294. doi:10.1002/ijc.20369 CrossRefPubMed

26.

Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9(2):827–836PubMed

27.

Kim B, Fatayer H, Hanby AM, Horgan K, Perry SL, Valleley EM, Verghese ET, Williams BJ, Thorne JL, Hughes TA (2013) Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One 8(5):e62766CrossRefPubMedPubMedCentral

28.

Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, Uzan S, Lotz JP, Touboul E, Lacave R (2006) Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94(4):473–480. doi:10.1038/sj.bjc.6602958 CrossRefPubMedPubMedCentral

29.

Ma H, Zhou H, Song X, Shi S, Zhang J, Jia L (2014) Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene 34:726–740. doi:10.1038/onc.2014.7

30.

Tanida S, Mizoshita T, Ozeki K, Tsukamoto H, Kamiya T, Kataoka H, Sakamuro D, Joh T (2012) Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012:862879-1–862879-8. doi:10.1155/2012/862879

31.

Park DC, Yeo SG, Shin EY, Mok SC, Kim DH (2006) Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103(3):996–1000CrossRefPubMed

32.

Hicks C, Kumar R, Pannuti A, Miele L (2012) Integrative analysis of response to tamoxifen treatment in ER-positive breast cancer using GWAS information and transcription profiling. Breast Cancer 6:47PubMedPubMedCentral

33.

Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH (2011) P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther 337(3):710–717CrossRefPubMed

34.

Teft WA, Mansell SE, Kim RB (2011) Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 39(3):558–562CrossRefPubMed

35.

Goler-Baron V, Sladkevich I, Assaraf YG (2012) Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol 83(10):1340–1348CrossRefPubMed

36.

Zheng T, Wang J, Chen X, Liu L (2010) Role of microRNA in anticancer drug resistance. Int J Cancer 126(1):2–10CrossRefPubMed

37.

Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79(6):817–824CrossRefPubMed

38.

Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P, Ralhan R (2010) CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 43(4):373–379CrossRefPubMed

Titel: Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer
verfasst von: Matvey M. Tsyganov
Maxim B. Freidin
Marina K. Ibragimova
Irina V. Deryusheva
Polina V. Kazantseva
Elena M. Slonimskaya
Nadezhda V. Cherdyntseva
Nikolai V. Litviakov
Publikationsdatum: 10.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3354-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer

Abstract

Purpose

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity

Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

Eribulin shows high concentration and long retention in xenograft tumor tissues

Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients

JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin

Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie